Introduction
============

Chemotherapy is one of the major standard treatment strategies for patients with advanced non-small cell lung cancer (NSCLC) [@B1]. It improves patient survival, but also produces a variety of toxic side effects among which liver injury is commonly experienced [@B2], [@B3]. The incidence of chemotherapy-related hepatotoxicity ranges from 12.1% to 80% based on different regiments and population [@B3]-[@B5]. While mild hepatic dysfunction usually improves without intervention, some patients experience severe hepatotoxicity that may demand treatment delay or suspension and can result in a worse prognosis. Deteriorated hepatic function may even increase the risk of other systemic side effects because drug metabolism is influenced by liver dysfunction. The so far reported data of chemotherapy-induced hepatotoxicity were mostly based on clinical trials with stringent inclusion criteria and limited sample size. It is therefore necessary to investigate broad scale chemotherapy related hepatotoxicity data in the real-world setting.

Hepatotoxicity following chemotherapy mostly attributes to either applied drugs or potential confounding diseases. Platinum-based doublet chemotherapy is the standard first-line regimen for patients with advanced lung cancer. Pemetrexed, docetaxel, gemcitabine, paclitaxel, and vinorelbine have been approved for first-line treatment of NSCLC, of which pemetrexed displays superior effectiveness and has become the preferential drug for lung adenocarcinomas. The rate of pemetrexed-related all grade hepatotoxicity was strikingly high in previous studies, ranging from 39.3-71% [@B6]-[@B8]. While the rate of hepatotoxicity caused by single anticancer drugs varies in clinical trials, the development of combination chemotherapy makes the situation more complex. Previous studies on leukemic, breast, and colon cancers have demonstrated that combined chemotherapy increases hepatic toxicity in patients [@B9]-[@B12]. However, we require a better understanding of the specific liver injury details associated with combination treatment in NSCLC, including clinical features, serum enzyme patterns, and differences among regimens.

With respect to preexisting risk factors for hepatotoxicity, viral hepatitis raises an important concern prior to chemotherapy administration. Hepatitis B reactivation was reported in up to 50% of hepatitis B surface antigen-positive patients who received chemotherapy, leading to hepatic decompensation and sacrifice in 5% of cases [@B13]. Younger age at diagnosis, abnormal liver function before chemotherapy, and chronic alcohol consumption are other risk factors for liver injury after chemotherapy [@B4], [@B14], and high-risk populations may require prophylaxis or intensive surveillance following chemotherapy.

Our study evaluated the risk factors and regimen related differences of hepatotoxicity during and post first-line doublet chemotherapy in patients with advanced lung adenocarcinomas. We investigated patients who were susceptible to liver dysfunction and the nature of hepatic toxicity across different regimens over time.

Methods
=======

Patients
--------

This retrospective study reviewed the medical records of patients with lung adenocarcinoma who were admitted to the hospital between January 2014 and December 2016. To investigate the incidence and risk factors of hepatic dysfunction during first-line chemotherapy and after first-line treatment, we designed a 2-stage study format. Enrolled patients were first included in the analyses of hepatotoxicity during first-line chemotherapy. Eligible patients were consecutively selected with inclusion criteria as follows: age ≥18 years, histologically or cytologically confirmed lung adenocarcinoma with stage IIIB/IV or recurrent disease, chemotherapy naive, receiving first-line double platinum-contained chemotherapy. Patients receiving prior epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) before first-line treatment or concurrent TKIs in first-line treatment were excluded from the stage 1 analysis. Totally 2108 patients were studied in the 1^st^ stage analysis. Within this group, regularly followed-up patients who received subsequent post first-line treatment without hepatotoxicity detected during first-line treatment were included in the 2^nd^ stage analyses.

Staging was determined according to the 7^th^ edition of TNM staging system. The dose of carboplatin was calculated by area under the curve and other chemotherapeutic agents were dosed based on body surface area. Clinical characteristics, including age, gender, Eastern Cooperative Oncology Group (ECOG) performance score (PS), stage, smoking status, chronic alcohol consumption history, the presence of pretreatment liver impairment, hepatitis B surface antigen (HBs-Ag) or hepatitis C antibody (HCV-Ab), and liver metastases were recorded for each patient. The primary endpoint of this study was the risk of all-types and all-grades of hepatotoxicity.

Liver function assessment
-------------------------

A liver function test was performed before and at least biweekly after chemotherapy administration. Parameters including aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin (TBL) were examined and results were reported as ULN values. Hepatotoxicity was graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0.

Statistical analysis
--------------------

Baseline characteristics were quantified through applying descriptive statistics. A chi-square or Fisher\'s exact test was utilized to compare categorical data, as appropriate. The association between variables and hepatic dysfunction during treatment were evaluated using a logistic regression analysis. To eliminate bias introduced by nonrandomized treatment assignments, patients who received first-line pemetrexed or non-pemetrexed doublet chemotherapy were matched 1:1 by the nearest-neighbor method. All statistical analyses were performed using SPSS 22.0 software (IBM, Armonk, NY, USA) and R version 3. 2. 2 (Institute for Statistics and Mathematics, Vienna, Austria; www. R-project.org) with R packages (MatchIt and foreign). A p-value less than 0.05 was considered statistically significant.

Results
=======

A total of 2108 patients were included in our analysis. The overall cohort was 54.9% male, with a median age of 60 years (IQR, 53-66 years). The majority of patients were of PS 0-1. At the time of final analysis, in December 2016, 892 patients receiving subsequent post first-line treatment were included in the second stage of analysis. Patients\' clinical characteristics are summarized in Table [1](#T1){ref-type="table"}.

Risk factors of liver dysfunction following first-line double platinum chemotherapy
-----------------------------------------------------------------------------------

The predictors of hepatotoxicity were examined in 2108 patients undergoing first-line therapy using logistic regression modeling. After adjusting for potential confounders, increased liver impairment was found to associate with younger age \< 65 years (OR, 2.398 \[95% CI, 1.755-3.275\]; P \< 0.001), pretreatment liver dysfunction (OR, 2.285 \[95% CI, 1.622-3.220\]; P \< 0.001), and pemetrexed-containing regimens (OR, 1.835 \[95% CI, 1.408-2.393\]; P \< 0.001) (Table [2](#T2){ref-type="table"}).

Comparison of hepatotoxicity frequency and severity between first-line patients with pemetrexed or non-pemetrexed doublet chemotherapy
--------------------------------------------------------------------------------------------------------------------------------------

Covariate differences between patients with either pemetrexed or non-pemetrexed (Gemcitabine, Vinorelbine, Paclitaxel, Docetaxel) regimens were compared. No significant differences were observed across all variables, with the exception that the pemetrexed regimen was more likely to be combined with carboplatin than the non-pemetrexed regimen. To rule out selection bias between the groups, covariates in the two groups were matched using propensity scores (Table [3](#T3){ref-type="table"}).

Before matching, a total of 316 (15.0%) liver dysfunction events occurred in the first analysis, of which 17 (0.8%) patients were diagnosed with grade 3-4 hepatotoxicity, and after matching, 844 cases in each group were included in the analysis. Liver dysfunction occurred in 247 (14.7%) patients during the first-line treatment, and among these patients, 14 (0.8%) were diagnosed with grade 3-4 hepatotoxicity. The incidence of liver dysfunction, across all grades, in patients with pemetrexed regimen was significantly greater than that of patients treated with non-pemetrexed regimens (P\<0.0001). Specifically, the incidence of hepatotoxicity in gemcitabine, vinorelbine, paclitaxel, or docetaxel-containing regimens was 64 (11.8%), 15 (9.0%), 9 (8.8%) and 3 (8.8%), respectively. However, with regard to hepatotoxicity above grade 3, no significant differences were observed between pemetrexed and non-pemetrexed groups (P=0.4220) (Table [4](#T4){ref-type="table"}).

Risk factors and incidences of liver dysfunction in post first-line treatments
------------------------------------------------------------------------------

Among 892 patients who received post first-line treatment, the median age was 60 years (IQR, 54-65 years). There were 147 (16.5%) events of liver dysfunction in this cohort, of which hepatotoxicity grade ≥3 occurred in 11 (1.2%) patients. Multivariate logistic regression analysis aimed at identifying hepatotoxicity risk factors revealed that younger age (\<65 years, OR, 1.699 \[95% CI, 1.081-2.672\]; P=0.022), pretreatment liver impairment (OR, 2.951 \[95% CI, 1.783-4.885\]; P\<0.001), presence of HBsAg or HCV-Ab (OR, 2.905 \[95% CI, 1.487-5.675\]; P= 0.002), and TKI therapy (OR, 2.621 \[95% CI, 1.809-3.798\]; P\<0.001) were independent hepatotoxicity risk factors (Table [5](#T5){ref-type="table"}).

Hepatotoxicity occurred in 25.2% (80/317) of patients who currently or previously received TKI therapy and in 11.6% (67/575) of patients who received chemotherapies alone (P\<0.0001). Hepatotoxicity above grade 3 occurred in 6 (1.9%) patients with TKI therapies and 5 (0.9%) patients receiving chemotherapy alone (P=0.5326).

Discussion
==========

The liver is particularly vulnerable to drug insults because this organ is where the majority of drug metabolism occurs. Limited but divergent data existed on the overall incidence and pattern of hepatotoxicity in patients with advanced lung adenocarcinomas. Our study demonstrated that up to one sixth of patients with adenocarcinoma developed liver dysfunction during treatment and the hepatotoxicity patterns suggested mostly mild hepatocellular damage. Increased hepatotoxic risk exists in patients with younger age, pretreatment liver impairment, and evidence of viral hepatitis. Different combination regimens possess different abilities to induce liver injury. Pemetrexed containing therapy exhibited a greater potential for hepatotoxicity than non-pemetrexed regimens during first-line treatment, and TKIs were found to increase hepatic toxicity in post first-line treatment.

The incidence of hepatotoxicity in patients with lung cancers varied by cohort. The prevalence of liver dysfunction in first-line and post first-line treatments in our study was 15.0% and 16.5%, respectively, which were similar to those observed in a previous study of patients with lung cancer who received chemotherapy [@B4]. However, we did not observe greater hepatotoxic events across treatment lines, which could possibly be explained through the following reasons. First, in the second stage analysis, we did not include patients who developed hepatic injury in the first-line treatment, whose risk of subsequent hepatic injury was predicted to be high, and as such, incidences of second-line hepatotoxicity might be underestimated. Second, therapeutic agent composition was different between the two stages, and divergent toxicity profiles of anticancer drugs may influence the overall incidence of hepatic toxicity. 60% of patients used pemetrexed as first-line treatment, while most post first-line cases received docetaxel chemotherapy. Moreover, TKIs were applied in approximately one third of patients in the second stage.

The theory that patients with preexisting liver diseases are prone to experience post- chemotherapy liver damage has been confirmed by our study [@B4], [@B14], and underlying diseases may include fatty liver disease, alcoholic hepatitis, viral hepatitis, or liver metastasis. We found that regardless of treatment cycles, chemotherapy or TKI therapy, patients with pretreatment liver impairment display a two-fold greater risk of hepatotoxicity. However, in our study, direct positive correlations were not observed between hepatotoxicity and specific conditions, such as alcohol assumption or liver metastases, which implies that the severity of liver injury plays a greater role than underlying conditions, since the liver has a strong compensation ability. Hepatic toxicity risk increased once liver injury, presented by elevated ALT, AST, or TBL levels, occurred prior to the chemotherapy. Previous studies have also revealed that metabolic status is another influencing factor, and high body mass index (BMI) and low high-density lipoprotein cholesterol (HDL-C) predict chemotherapy-related hepatic dysfunction [@B3], [@B15].

It is noticeable that hepatitis reactivation gains more attention, as this is a well-recognized complication in patients who are infected with the virus and undergo cytotoxic chemotherapy, however HBV reactivation seems more common than HCV reactivation [@B16]. In lung cancer, hepatitis B reactivation was reported in up to 38% of patients who were hepatitis B surface antigen positive and received chemotherapy [@B17], which may lead to hepatic decompensation and even death [@B16]. In our cohort, the prevalence of HBsAg and hepatitis C antibodies were found to be 5.4%, in agreement with a previous report from a hepatitis prevalent region [@B4]. Although we did not dynamically monitor the replicative status of hepatitis virions, our results reveal that patients who present HBs-Ag or HBcAb are more likely to develop hepatotoxicity after multiple chemotherapy exposures. In other words, the potential for hepatotoxicity elevates with prolonged treatment because of increased liver burden. Our observation is in accordance with a previous study on patients with breast cancer, which found that HBV reactivation appeared at a median of 2.5 chemotherapy cycles. Antiviral prophylaxis has proven to benefit patients with cancer who are at risk for HBV reactivation [@B17].

In the present study, more occurrences of hepatotoxicity were observed through pemetrexed-based chemotherapy than other platinum-doublet regimens. However, in most cases, these hepatic events tended to be mild and reversible. Indeed, previous studies have demonstrated that pemetrexed alone caused a strikingly high incidence of hepatic toxicity. In the phase II trial in chemotherapy-naïve patients with advanced non-small-cell lung cancer, 600 mg/m^2^ pemetrexed caused asymptomatic hepatotoxicity in 80% of patients, with elevations of hepatic biochemistry of up to 20-fold of normal values in 14% of patients [@B5]. In clinical trials of 500 mg/m^2^ standard pemetrexed dose, all grades of transaminase elevation were found in 7.9 to 71% of previously treated patients, which mostly occurred during the first cycle, and 1.9 to 16.7% of patients presented grade 3/4 hepatotoxicity [@B8], [@B18]-[@B20]. Patients who received pemetrexed were more likely to display grade 3/4 hepatic toxicity compared to those under docetaxel [@B19]. When combination therapies were administered, pemetrexed-based regimens displayed numerically higher incidences of mild grade ALT elevation [@B7], [@B21], however there were no significant difference in grade 3/4 ALT alterations between pemetrexed and docetaxel doublet regimens [@B22]. In agreement with previous findings, our study confirmed that pemetrexed-based doublet chemotherapy was associated with more mild hepatotoxicities than other therapies, although we did not observe differences with respect to severe hepatic events.

While the mechanism of liver injury that occurs during pemetrexed application has not been fully elucidated, enzymes involved in folate metabolism maybe the crucial factors. These enzymes exist in both liver and tumor cells, and therefore, pemetrexed may affect liver cells [@B7]. While modulation of pemetrexed dose intensity and administration schedule allows adequate treatment without adversely affecting transaminase levels [@B5], a small proportion of patients still require treatment delays, dose adjustments, or discontinuation in the subsequent cycles [@B7].

Liver dysfunction occurred more frequently during TKI treatment than chemotherapy [@B23], [@B24]. Our study demonstrated that approximately one quarter of post first-line patients who took TKIs developed liver injury, which was significantly more than those who underwent chemotherapy alone. However, the rate of hepatotoxicity in this study seemed uncomparable with that reported in other studies, primarily because incidences of TKI-related hepatotoxicities substantially differed among studies and varied from 6 to 62% for all grade and 0 to 19% for grades \>3 [@B25]-[@B30]. The type of TKI and therapy duration may affect the frequency of liver toxicity. Gefitinib displayed a significantly higher frequency of grade ≥ 3 hepatotoxicity compared with erlotinib or afatinib [@B29], [@B31]. Clinically significant fatal liver failure was also observed in patients receiving TKIs [@B28], [@B32], and greater extents of hepatotoxicities were found when observation period endured for more than 14 months [@B33].

Our findings that neither aging nor gender were risk factors to hepatotoxicity did not support the persistent assumptions that drug-induced hepatotoxicity increased in the older ages and women. However, this result is partly in line with the previous findings on drug-induced liver injury and there have several possible explanations for this result [@B4], [@B34]. First, in the current study, patients ≥ 65 years had a more prominent male predominance (59.5% vs. 52.9%, p=0.0057) than the younger patients, which may counteract the effect of aging and gender on hepatotoxicity. Second, the fact that younger age was associated with cytolytic damage while older age was a determinant for cholestatic damage may explain the susceptibility of younger patients in our study because chemotherapy or TKI-induced liver damage were mostly represented as hepatocellular injury. Third, elderly patients tend to have more chemotherapy-associated adverse events such as neutropenia, anemia and thrombocytopenia, which usually cause a suspension or delay of chemotherapy and might affect the incidence of hepatotoxicity.

Our study had several limitations. First, a majority of patients were treated with pemetrexed because of its proven effectiveness in lung adenocarcinoma across previous studies. However, we attempted to include as many patients as possible. Second, due to the retrospective nature of our investigation, potentially critical covariate information might be missing. Third, we did not observe patient outcomes, due to limited follow-up time.

Conclusions
===========

Patients with advanced lung adenocarcinomas with younger age, pretreatment liver impairment, and viral hepatitis are at risk of hepatotoxicity. Pemetrexed and TKIs should be used with caution, especially in patients at risk of hepatic impairment.
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EGFR-TKIs

:   epidermal growth factor receptor-tyrosine kinase inhibitors

NSCLC

:   non-small cell lung cancer

PS

:   performance score

HBs-Ag

:   hepatitis B surface antigen

HCV-Ab

:   hepatitis C antibody

AST

:   aspartate aminotransferase

ALT

:   alanine aminotransferase

TBL

:   total bilirubin.

###### 

Patient characteristics.

  Variable                        All patients (n=2108)   Patients in the 2^nd^ stage analysis (n=892)
  ------------------------------- ----------------------- ----------------------------------------------
  Age, median (IQR)               60 (53-66)              60 (54-65)
  Age                                                     
  \< 65 years                     1481 (70.3)             638 (71.5)
  ≥ 65 years                      627 (29.7)              254 (28.5)
  Gender                                                  
  Male                            1157 (54.9)             480 (53.8)
  Female                          951 (45.1)              412 (46.2)
  ECOG PS                                                 
  0\~1                            2100 (99.6)             886 (99.3)
  2                               8 (0.4)                 6 (0.7)
  Stage                                                   
  IIIB                            470 (22.3)              101 (11.3)
  IV                              1370 (65.0)             587 (65.8)
  Recurrent                       268 (12.7)              204 (22.9)
  Pretreatment liver impairment                           
  No                              1891 (89.7)             799 (89.6)
  Yes                             217 (10.3)              93 (10.4)
  Smoking status                                          
  Never                           1439 (68.3)             611 (68.5)
  Ever                            699 (31.7)              281 (31.5)
  Drinking history                                        
  No                              1996 (94.7)             854 (95.7)
  Yes                             112 (5.3)               38 (4.3)
  HBs-Ag or HCV-Ab                                        
  Absent                          1994 (94.6)             846 (94.8)
  Present                         114 (5.4)               46 (5.2)
  Liver metastasis                                        
  No                              1990 (94.4)             818 (91.7)
  Yes                             118 (5.6)               74 (8.3)
  Chemotherapy                                            
  Non-pemetrexed                  863 (40.9)              
  Pemetrexed                      1245 (59.1)             
  TKI therapy                                             
  No                                                      744 (83.4)
  Yes                                                     148 (16.6)

###### 

Logistic regression analysis for occurrences of liver dysfunction in 2108 patients undergoing first-line double platinum chemotherapy.

  Variable                        Liver dysfunction, No.   Univariable analysis   Multivariable analysis                                 
  ------------------------------- ------------------------ ---------------------- ------------------------ ------- --------------------- -------
                                  No                       Yes                                                                           
  Age                                                                                                      0.000                         0.000
  ≥ 65 years                      572                      55                     Reference                        Reference             
  \< 65 years                     1220                     261                    2.225 (1.636-3.025)              2.398 (1.755-3.277)   
  Gender                                                                                                   0.576                         
  Male                            979                      178                    Reference                                              
  Female                          813                      138                    0.934 (0.734-1.188)                                    
  Smoking status                                                                                           0.667                         
  Never                           1220                     219                    Reference                                              
  Ever                            572                      97                     0.945 (0.729-1.224)                                    
  Drinking history                                                                                         0.093                         0.127
  No                              1703                     293                    Reference                        Reference             
  Yes                             89                       23                     1.502 (0.934-2.415)              1.463 (0.898-2.383)   
  Pretreatment liver impairment                                                                            0.000                         0.000
  No                              1630                     261                    Reference                        Reference             
  Yes                             162                      55                     2.120 (1.520-2.957)              2.285 (1.622-3.220)   
  HBs-Ag or HCV-Ab                                                                                         0.806                         
  Absent                          1696                     298                    Reference                                              
  Present                         96                       18                     1.067 (0.636-1.792)                                    
  Liver metastases                                                                                         0.329                         
  No                              1688                     302                    Reference                                              
  Yes                             104                      14                     0.752 (0.425-1.332)                                    
  Chemotherapy                                                                                             0.000                         0.000
  Non-Pemetrexed                  771                      92                     Reference                        Reference             
  Pemetrexed                      1021                     224                    1.839 (1.418-2.385)              1.835 (1.408-2.393)   

###### 

Comparison of variables before and after propensity score matching in patients undergoing first-line double platinum chemotherapy.

  Variable                        Before matching   After matching                                        
  ------------------------------- ----------------- ---------------- ---------- ------------ ------------ ----------
  Age                                                                0.1285                               \>0.9999
  \< 65 years                     859 (69.0)        622 (72.1)                  622 (73.7)   622 (73.7)   
  ≥ 65 years                      386 (31.0)        241 (27.9)                  222 (26.3)   222 (26.3)   
  Gender                                                             0.3131                               0.5243
  Male                            672 (54.0)        485 (56.2)                  462 (54.7)   475 (56.3)   
  Female                          573 (46.0)        378 (43.8)                  382 (45.2)   369 (43.7)   
  ECOG PS                                                            \>0.9999                             \>0.9999
  0\~1                            1240 (99.6)       860 (99.7)                  841 (99.6)   841 (99.6)   
  2                               5 (0.4)           3 (0.3)                     3 (0.4)      3 (0.4)      
  Smoking status                                                     0.1792                               0.1753
  Never                           864 (69.4)        575 (66.6)                  586 (69.4)   560 (66.4)   
  Ever                            381 (30.6)        288 (33.4)                  258 (30.6)   284 (33.6)   
  Drinking history                                                   0.9767                               0.8285
  No                              1179 (94.7)       817 (94.7)                  800 (94.8)   798 (94.5)   
  Yes                             66 (5.3)          46 (5.3)                    44 (5.2)     46 (5.5)     
  Pretreatment liver impairment                                      0.2965                               0.4789
  No                              1124 (90.3)       767 (88.9)                  758 (89.8)   749 (88.7)   
  Yes                             121 (9.7)         96 (11.1)                   86 (10.2)    95 (11.3)    
  HBs-Ag or HCV-Ab                                                   0.9486                               \>0.9999
  Absent                          1178 (94.6)       816 (94.6)                  798 (94.5)   798 (94.5)   
  Present                         67 (5.4)          47 (5.4)                    46 (5.5)     46 (5.5)     
  Liver metastases                                                   0.8940                               \>0.9999
  No                              1176 (94.5)       814 (94.3)                  797 (94.4)   797 (94.4)   
  Yes                             69 (5.5)          49 (5.7)                    47 (5.6)     47 (5.6)     
  Platinum                                                           \<0.0001                             \>0.9999
  Cisplatin                       297 (23.9)        295 (34.2)                  276 (32.7)   276 (32.7)   
  Carboplatin                     948 (76.1)        568 (65.8)                  568 (67.3)   568 (67.3)   

###### 

Comparisons of liver dysfunction in different combination chemotherapies in the first-line treatment after matching.

  Characteristic   Patient No.   All grade events (%)   ≥ 3 grade events (%)
  ---------------- ------------- ---------------------- ----------------------
  All              1688          247 (14.6)             14 (0.8)
  Pemetrexed       844           156 (18.5)             9 (1.1)
  Non-pemetrexed   844           91 (10.8)              5 (0.6)
  Gemcitabine      541           64 (11.8)              1 (0.2)
  Vinorelbine      167           15 (9.0)               3 (1.8)
  Paclitaxel       102           9 (8.8)                0 (0)
  Docetaxel        34            3 (8.8)                1 (2.9)

###### 

Logistic regression analysis of risk factor of hepatotoxicity in 892 patients receiving post first-line double treatment.

  Variable                        Liver dysfunction, No.   Univariable analysis   Multivariable analysis                                   
  ------------------------------- ------------------------ ---------------------- ------------------------ --------- --------------------- ---------
                                  No                       Yes                    Odds Ratio (95% CI)      P value   Odds Ratio (95% CI)   P value
  Age                                                                                                      0.006                           0.022
  \< 65 years                     519                      119                    1.851 (1.192-2.874)                1.699 (1.081-2.672)   
  ≥ 65 years                      226                      28                     Reference                          Reference             
  Gender                                                                                                   0.731                           
  Male                            399                      81                     Reference                                                
  Female                          346                      66                     0.940 (0.659-1.341)                                      
  Smoking status                                                                                           0.601                           
  Never                           513                      98                     Reference                                                
  Ever                            232                      49                     1.106 (0.759-1.611)                                      
  Drinking history                                                                                         0.742                           
  No                              714                      140                    Reference                                                
  Yes                             31                       7                      1.152 (0.497-2.667)                                      
  Pretreatment liver impairment                                                                            0.000                           0.000
  No                              682                      117                    Reference                          Reference             
  Yes                             63                       30                     2.776 (1.723-4.472)                2.951 (1.783-4.885)   
  HBs-Ag or HCV-Ab                                                                                         0.000                           0.002
  Absent                          716                      130                    Reference                          Reference             
  Present                         29                       17                     3.229 (1.724-6.045)                2.905 (1.487-5.675)   
  Liver metastases                                                                                         0.215                           
  No                              687                      131                    Reference                                                
  Yes                             58                       16                     1.447 (0.807-2.595)                                      
  TKI therapy                                                                                              0.000                           0.000
  No                              508                      67                     Reference                          Reference             
  Yes                             237                      80                     2.559 (1.787-3.666)                2.621 (1.809-3.798)   
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